Cinta H. C.
- Country
- Spain
- Department
- Oncología Médica
Research Overview
- Evaluation of FS120 Monotherapy and FS120 with Pembrolizumab in Patients with Advanced Malignancies: A First-in-Human Safety and Efficacy Study
- Phase 1/2a Study of BMS-986523 Monotherapy and Combination Therapy in Participants with KRAS-Altered Advanced Solid Malignancies
- Phase 1/2 Study of BMS-986466 with Adagrasib ± Cetuximab in KRAS G12C-Mutant Advanced Solid Tumors
Data & Insights
Has run more than one trial at 65 of 161 partner sites.
Specializations
Gastrointestinal Oncology
This investigator specializes in treating advanced gastric and gastroesophageal junction adenocarcinomas, with particular focus on HER2-overexpressing tumors. Their research encompasses novel therapeutic approaches for patients who have progressed after initial treatments.
- Advanced Gastric Cancer
- Gastroesophageal Junction Tumors
- Pancreatic Ductal Adenocarcinoma
Thoracic Oncology
The investigator conducts research in non-small cell lung cancer, with specific interest in targeted therapies for patients with KRAS G12C mutations. Their work includes evaluation of novel therapeutic combinations and immunotherapy approaches.
- Advanced NSCLC
- Targeted Molecular Therapies
- Combination Treatment Strategies
Advanced Solid Tumors
Research activities focus on early-phase clinical development of novel therapeutic agents for various solid malignancies, including evaluation of antibody-drug conjugates and innovative combination approaches.
- First-in-Human Studies
- Novel Therapeutic Combinations
- Refractory Solid Tumors
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.